chrX-123184533-A-AG
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 2P and 8B. PM2BP6_Very_Strong
The NM_000828.5(GRIA3):c.-2dup variant causes a 5 prime UTR change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: not found (cov: 21)
Consequence
GRIA3
NM_000828.5 5_prime_UTR
NM_000828.5 5_prime_UTR
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 6.32
Genes affected
GRIA3 (HGNC:4573): (glutamate ionotropic receptor AMPA type subunit 3) Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. These receptors are heteromeric protein complexes composed of multiple subunits, arranged to form ligand-gated ion channels. The classification of glutamate receptors is based on their activation by different pharmacologic agonists. The subunit encoded by this gene belongs to a family of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate)-sensitive glutamate receptors, and is subject to RNA editing (AGA->GGA; R->G). Alternative splicing at this locus results in different isoforms, which may vary in their signal transduction properties. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP6
Variant X-123184533-A-AG is Benign according to our data. Variant chrX-123184533-A-AG is described in ClinVar as [Benign]. Clinvar id is 167157.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
GRIA3 | NM_000828.5 | c.-2dup | 5_prime_UTR_variant | 1/16 | ENST00000622768.5 | ||
GRIA3 | NM_007325.5 | c.-2dup | 5_prime_UTR_variant | 1/16 | ENST00000620443.2 | ||
GRIA3 | NM_001256743.2 | c.-2dup | 5_prime_UTR_variant | 1/4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
GRIA3 | ENST00000620443.2 | c.-2dup | 5_prime_UTR_variant | 1/16 | 1 | NM_007325.5 | P4 | ||
GRIA3 | ENST00000622768.5 | c.-2dup | 5_prime_UTR_variant | 1/16 | 5 | NM_000828.5 | A1 |
Frequencies
GnomAD3 genomes Cov.: 21
GnomAD3 genomes
Cov.:
21
GnomAD3 exomes AF: 1.00 AC: 183515AN: 183516Hom.: 57785 AF XY: 1.00 AC XY: 67944AN XY: 67944
GnomAD3 exomes
AF:
AC:
183515
AN:
183516
Hom.:
AF XY:
AC XY:
67944
AN XY:
67944
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome Cov.: 29
GnomAD4 exome
Cov.:
29
GnomAD4 genome Cov.: 21
GnomAD4 genome
Cov.:
21
Alfa
AF:
Hom.:
Asia WGS
AF:
AC:
2522
AN:
2522
ClinVar
Significance: Benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | May 03, 2018 | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | Nov 19, 2019 | - - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Aug 14, 2012 | - - |
Syndromic X-linked intellectual disability 94 Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Aug 10, 2021 | - - |
Inborn genetic diseases Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 24, 2014 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at